INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,771,441 | +120.2% | 95,547 | +31.3% | 0.00% | – |
| Q2 2023 | $804,560 | -19.5% | 72,745 | -2.3% | 0.00% | – |
| Q1 2023 | $999,984 | -49.3% | 74,459 | -53.3% | 0.00% | -100.0% |
| Q4 2022 | $1,972,557 | -9.4% | 159,463 | +2.2% | 0.00% | 0.0% |
| Q3 2022 | $2,177,000 | +0.1% | 156,087 | -0.9% | 0.00% | 0.0% |
| Q2 2022 | $2,175,000 | -14.7% | 157,510 | +0.5% | 0.00% | 0.0% |
| Q1 2022 | $2,550,000 | +0.9% | 156,715 | +1.0% | 0.00% | 0.0% |
| Q4 2021 | $2,527,000 | +226.5% | 155,108 | +197.5% | 0.00% | – |
| Q3 2021 | $774,000 | -88.3% | 52,143 | +1.1% | 0.00% | -100.0% |
| Q1 2016 | $6,628,000 | -31.3% | 51,588 | -20.2% | 0.00% | -40.0% |
| Q4 2015 | $9,654,000 | -10.6% | 64,644 | -0.7% | 0.01% | -16.7% |
| Q3 2015 | $10,796,000 | -99.9% | 65,093 | -18.2% | 0.01% | -40.0% |
| Q2 2015 | $19,209,503,000 | -22.8% | 79,582 | -9.8% | 0.01% | -23.1% |
| Q1 2015 | $24,873,600,000 | +84.9% | 88,198 | +2.3% | 0.01% | +85.7% |
| Q4 2014 | $13,449,072,000 | +826.8% | 86,212 | +1859.4% | 0.01% | +600.0% |
| Q1 2014 | $1,451,076,000 | – | 4,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |